Market Research Logo

Type 2 Diabetes - Pipeline Review, H1 2018

Type 2 Diabetes - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2018, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type2 diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 29, 63, 72, 6, 220, 65 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 18 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Type2 diabetes - Overview
Type2 diabetes - Therapeutics Development
Type2 diabetes - Therapeutics Assessment
Type2 diabetes - Companies Involved in Therapeutics Development
Type2 diabetes - Drug Profiles
Type2 diabetes - Dormant Projects
Type2 diabetes - Discontinued Products
Type2 diabetes - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Type2 diabetes, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Type2 diabetes - Pipeline by Adocia SAS, H1 2018
Type2 diabetes - Pipeline by Aegis Therapeutics LLC, H1 2018
Type2 diabetes - Pipeline by AFFiRiS AG, H1 2018
Type2 diabetes - Pipeline by Akcea Therapeutics Inc, H1 2018
Type2 diabetes - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
Type2 diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018
Type2 diabetes - Pipeline by Amgen Inc, H1 2018
Type2 diabetes - Pipeline by Aphios Corp, H1 2018
Type2 diabetes - Pipeline by Arecor Ltd, H1 2018
Type2 diabetes - Pipeline by Arena Pharmaceuticals Inc, H1 2018
Type2 diabetes - Pipeline by AstraZeneca Plc, H1 2018
Type2 diabetes - Pipeline by AusBio Ltd, H1 2018
Type2 diabetes - Pipeline by Avadel Pharmaceuticals Plc, H1 2018
Type2 diabetes - Pipeline by Bayer AG, H1 2018
Type2 diabetes - Pipeline by Betagenon AB, H1 2018
Type2 diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018
Type2 diabetes - Pipeline by Biocon Ltd, H1 2018
Type2 diabetes - Pipeline by BioLingus AG, H1 2018
Type2 diabetes - Pipeline by BioRestorative Therapies Inc, H1 2018
Type2 diabetes - Pipeline by Biozeus, H1 2018
Type2 diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018
Type2 diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Type2 diabetes - Pipeline by Boston Therapeutics Inc, H1 2018
Type2 diabetes - Pipeline by Braasch Biotech LLC, H1 2018
Type2 diabetes - Pipeline by Bristol-Myers Squibb Co, H1 2018
Type2 diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2018
Type2 diabetes - Pipeline by Cadila Healthcare Ltd, H1 2018
Type2 diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H1 2018
Type2 diabetes - Pipeline by Caelus Health, H1 2018
Type2 diabetes - Pipeline by Cardax Inc, H1 2018
Type2 diabetes - Pipeline by Carmot Therapeutics Inc, H1 2018
Type2 diabetes - Pipeline by Cellix Bio Pvt Ltd, H1 2018
Type2 diabetes - Pipeline by Celon Pharma SA, H1 2018
Type2 diabetes - Pipeline by Center Laboratories Inc, H1 2018
Type2 diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2018
Type2 diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Type2 diabetes - Pipeline by Cinnagen Co, H1 2018
Type2 diabetes - Pipeline by CJ HealthCare Corp, H1 2018
Type2 diabetes - Pipeline by CohBar Inc, H1 2018
Type2 diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H1 2018
Type2 diabetes - Pipeline by CymaBay Therapeutics Inc, H1 2018
Type2 diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Type2 diabetes - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Type2 diabetes - Pipeline by Dance Biopharm Inc, H1 2018
Type2 diabetes - Pipeline by Delpor Inc, H1 2018
Type2 diabetes - Pipeline by Diabetology (Products) Ltd, H1 2018
Type2 diabetes - Pipeline by Diamyd Medical AB, H1 2018
Type2 diabetes - Pipeline by Diasome Pharmaceuticals Inc, H1 2018
Type2 diabetes - Pipeline by DiscoveryBiomed Inc, H1 2018
Type2 diabetes - Pipeline by DNJ Pharma Inc, H1 2018
Type2 diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018
Type2 diabetes - Pipeline by Elcelyx Therapeutics Inc, H1 2018
Type2 diabetes - Pipeline by Eli Lilly and Co, H1 2018
Type2 diabetes - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018
Type2 diabetes - Pipeline by Energenesis Biomedical Co Ltd, H1 2018
Type2 diabetes - Pipeline by Enteris BioPharma Inc, H1 2018
Type2 diabetes - Pipeline by Enzene Biosciences Ltd, H1 2018
Type2 diabetes - Pipeline by Enzo Biochem Inc, H1 2018
Type2 diabetes - Pipeline by Epichem Pty Ltd, H1 2018
Type2 diabetes - Pipeline by Eternygen GmbH, H1 2018
Type2 diabetes - Pipeline by Evotec AG, H1 2018
List of Figures
Number of Products under Development for Type2 diabetes, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report